It is also a preferred choice for automotive manufacturers as a warning of potential safety hazards.

China has been assessed and certified as meeting the requirements of 麟 ISO 13485:2016 EN ISO 13485:2016 ’骥鑫馨瓤） For the foiowing actratEes Design and manufacture of medical grade thermoplastic elastomers for non-active medical devices and active medical devices 遴；舞蒸；撇蒸 (non-implantable) ：护、：：于 b入沙黔娜；舞睡莎：器器舞蟒檬非拟拐称群亘爸竺舀‘。

By 2030, Avient will enable 100% of our products manufactured for packaging applications to be recyclable or reusable to advance the circular economy.

They are constructed from layers of 0°/90° woven E-glass fiber reinforcements combined with a proprietary resin system in a continuous pultrusion manufacturing process.

Prefab (Prefabricated): Components or entire structures manufactured in a factory setting before being transported and assembled on-site. For example, transporting oversized prefab units from the manufacturing facility to the construction site may cross several state lines. It also enables greater quality consistency because weather is no longer a factor and the manufacturing environment is controlled.

Retired Chief Financial and Planning Officer of Eaton plc (“Eaton”), a global manufacturing company. Nicolas’ experience in managing manufacturing in the Asia Pacific region can assist Avient with our manufacturing plans in that region. Retired Chief Technology Officer for Colgate-Palmolive Company (“Colgate- Palmolive”), a leading consumer products manufacturer.

DISCLAIMER Avient Corporation 3 Avient Corporation 4 Welcome Bob Patterson Chairman, President, and Chief Executive Officer INTRODUCTION Sustainability for a Better Tomorrow Jamie Beggs Senior Vice President and Chief Financial Officer Avient Corporation 5 WE ARE A FORMULATOR CUSTOM FORMULATION Avient Corporation 6 Avient Corporation 7 WE ARE INNOVATORS 2,500+ ACTIVE PATENT FILINGS WORLDWIDE 1,100+ RESEARCH AND DEVELOPMENT ASSOCIATES >85% Stage-gate technology projects enable sustainable solutions INDIA INNOVATION CENTER 33% 2022 VITALITY INDEX 140+ MATERIAL SCIENCE PhD ASSOCIATES Avient Corporation 8 3% 3% 5% Avient Specialty Formulators Other Specialty / Chemical Companies CAPEX / Revenue 2023E Global footprint enables greater flexibility to exceed needs of customers and deliver localized technical and formulation expertise 35 9 36 24 Manufacturing Locations by Region WE ARE ASSET LIGHT Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA Avient Corporation 9 Asset-light flexibility enables more nimble manufacturing capabilities and lower overhead Periods of economic weakness have driven higher levels of cash generation due to working capital improvement PROVEN TRACK RECORD OF HIGH FREE CASH FLOW CONVERSION 78% 78% 80% 80% 81% 78% 84% 83% 80% 79% 50% 55% 60% 65% 70% 75% 80% 85% 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023E 0 50 100 150 200 250 300 350 400 Fr ee C as h Fl ow C on ve rs io n Fr ee C as h Fl ow FC F $ AVNT FC F Conver si on % S&P F CF Conversion % 2 Recent Divestitures - Combined $1.7B in Proceeds PORTFOLIO EVOLUTION Avient Corporation 10 Combined $3.6B Investment in Acquisitions Since 2016 Color Business Distribution 2016 2022 PORTFOLIO TRANSFORMATION 7% 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d EB IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications Avient Corporation 11 END MARKET TRANSFORMATION Packaging Consumer Healthcare Defense Avient Corporation 12 10% 19% 8% 23% 4% 7% 7% 2006 2023E Other Industri es 78% Healthcare Consumer Packaging 22% 56% 14% 10% 43% 9% 2006 2023E Reduced Exposure to Cyclical End Markets End Market Diversification Transportation Building & Construction 57% 19% Defense IMPROVING PROFITABILITY AND EXPANDING MARGINS Avient Corporation 13 Adj. CAFE: Corporate Average Fuel Economy >50% Improvement REDUCE – TAKEAWAY Reducing Energy Consumption and Dependence on Fossil Fuels Drives Growth Projections Examples Covered Today 45% Other Applications 55% 2022PF $310M 38 46 CAFE1 Miles Per Gallon Proposed Requirements HOW WE ENABLE SUSTAINABILITY Preserve Woon Keat Moh Senior Vice President, President of Color, Additives and Inks – Americas and Asia Avient Corporation 61 PRESERVE Avient Corporation 62 KEY CUSTOMER CHALLENGES: • Preserving Key Natural Resources - Companies are being challenged to mitigate high environmental impact processes such as water-intensive textile dyeing or food spoilage • Incorporating Renewable Materials - Adoption of bio-based raw materials requires design and formulation expertise to overcome performance shortcomings of neat resins • Increasing Healthcare Regulations - Utilizing sustainable materials in healthcare applications requires considerable support in navigating complex regulatory requirements • Increasing Regulatory Compliance - Non-Intentionally Added Substances (NIAS) need to be controlled in sensitive applications • Enabling Faster and More Reliable Connectivity – Substantial investments in 5G infrastructure are required to unlock the potential of the Internet of Things Solutions to preserve and protect natural resources & human life Avient Corporation 63 Spin Dyed Precolor Textile Yarn Renol™ Spin Dyeing Colorants • Replaces water-based dye processes to reduce waste creation • Conserves water and energy 75% LESS WATER PROTECTIVE DENIM Dyneema® Workwear Solutions • Improves tear resistance 50-100% • More protective than competitive alternatives • Enables the amount of protective fiber to be reduced without sacrificing performance 600% IMPROVED ABRASION RESISTANCE Clothing & Textiles 2022 Revenue: $49M Avient Corporation 64 Low Cure Textile Inks Avient Specialty Inks™ Low Cure Inks • Decreases energy consumption • Reduces scrap due to heat-related defects SAVES ENERGY Clothing & Textiles 2022 Revenue: $40M BIO-BASED FORMULATIONS Water Based Textile Inks Zodiac™ Aquarius™ Specialty Inks • Incorporates bio-based materials • Non-formaldehyde solutions available • Reduces waste by enabling high open screen time Avient Corporation 65 Mosquito Netting Cesa™ Fiber Anti-Mosquito Additives • Helps control malaria • Protects consistently using a controlled release of insecticide • Expands access to healthcare breakthroughs to global communities ANNUAL NEW MALARIA CASES 200 Million Antimicrobial Protection Cesa™ WithStand™ Antimicrobial Additives • Reduces microbial / mold growth • Helps reduce odor, staining, discoloration • Excellent comfort and wearability • Chemical resistance - will not discolor or degrade REDUCES MICROBES Human Health & Safety 2022 Revenue: $5M Avient Corporation 66 Cut-Resistant Gloves Dyneema® Solutions • Incorporates bio-based materials • Reduces carbon emissions • Excellent wearability / comfort WORK INJURIES REDUCES Rescue Rope Dyneema® Solutions • Superior strength-to-weight ratio • High break load • Extraordinary reliability SAVES LIVES Human Health & Safety 2022 Revenue: $106M Body Armor Dyneema® Protective Solutions • Exceptional trauma protection • Excellent wearability LIGHTER THAN ARAMID FIBER 35% Avient Corporation 67 40% BIO-DERIVED Pharmaceutical Tubing Versaflex™ Healthcare Pharma Tubing Formulations NEU™ Specialty Engineered Materials • Facilitates incorporation of sustainable materials with healthcare device manufacturers • Eliminates vulcanization processes Medical 2022 Revenue: $40M NON-PHTHALATE Respiratory Conduit Versaflex™ Healthcare Corrugated Tubing Formulations • Non-Phthalate • ISO 10993 & USP Class VI compliant Avient Corporation 68 100% UP TO BIO-BASED CARRIER Medical Devices Mevopur™ Bio-Based Colorants • Minimizes risk through pre-testing • Provides vital regulatory compliance • Minimizes global supply chain risk with validated backup supply Continuous Glucose Monitoring and Auto Injectors Trilliant™ Healthcare Polymer Solutions • Impact performance • Chemical resistance ENABLES HOME CARE Medical 2022 Revenue: $16M Avient Corporation 69 Fiber Optic Cable and Jacketing Fiber-Line™ Optical Fiber Cable Components • Reduction in weight & energy usage • Thermal and abrasion resistant • Extends product life ENABLES CONNECTIVITY Cable Micromodules ECCOH™ Low Smoke Formulations • Non-halogen • Low smoke and toxicity SUPPORTS SUSTAINABLE INFRASTRUCTURE Base Station Components Edgetek™ Low-Density Formulations • Low density – lighter weight • Low warpage & thermal conductivity EXTENDS PRODUCT LIFE Antenna Components PREPERM™ Low Loss Dielectric Formulations • Replaces costly ceramics • Consistent and efficient antenna performance ENHANCES PERFORMANCE 5G Infrastructure 2022 Revenue: $39M Avient Corporation 70 “Nike has partnered with Avient extensively over the years because of their leadership in eco-friendly screen printing inks.” Per Carlsson, Manufacturing and Operations CUSTOMER TESTIMONIALS Avient Corporation 71 50 90 0 20 40 60 80 100 2022 2030 Medical Plastics Market Size PRESERVE – TAKEAWAY Protecting Human Life and Enabling Connectivity Drives Growth Projections Examples Covered Today 56% Other Applications 44% 2022 $525M (i n $B ill io ns ) 8% CAGR 34% CAGR 5G Infrastructure Market Size 12 92 0 10 20 30 40 50 60 70 80 90 100 2023 2024 2025 2026 2027 2028 2029 2030 (in $ B ill io ns ) Source: Grand View Research Source: Global Data Summary Jamie Beggs Senior Vice President and Chief Financial Officer Avient Corporation 72 OUR SUSTAINABILITY REPORT Avient Corporation 73 Avient Corporation 74 2030 SUSTAINABILITY GOALS Avient Corporation 75 PERFORMANCE AND RECOGNITION 1 2 5 ESG Ratings Performance ESG Awards and Certifications top 13% 94th percentile Avient Corporation 76 SUSTAINABILITY INNOVATION AWARDS Ultra-Low Carbon Footprint TPE Innovation Award, Finalist: Plastics Industry Association PCR Colorants + Additives Sustainable Packaging Innovation, Finalist: U.S.

Value-Added Services & Solutions With a wealth of experience in polymer research and technology, we are prepared to handle the most challenging problems facing medical manufacturers. Value-Added Services & Solutions With a wealth of experience in polymer research and technology, we are prepared to handle the most challenging problems facing medical manufacturers.

All materials were pre-dried and molded to the specifications provided by the manufacturer. With regards to PC alloys, the general trend of increasing chemical resistance was observed in order of PC/ABS < PC/PET < PC/PBT, which was expected based on previous research and the marketing literature of PC blend manufacturers.4 However, the Edgetek ET8900 series clearly demonstrated the best ESCR performance against the household cleaners.

Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to:  The final amount of charges resulting from the planned manufacturing realignment and the Company’s ability to realize anticipated savings and operational benefits from the asset realignment;  Our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies;  Our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive;  Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future;  The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability;  The speed and extent of an economic recovery, including the recovery of the housing market;  Our ability to achieve new business gains;  The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks;  Changes in polymer consumption growth rates in the markets where we conduct business;  Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online;  Fluctuations in raw material prices, quality and supply and in energy prices and supply;  Production outages or material costs associated with scheduled or unscheduled maintenance programs;  Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters;  An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services;  An inability to raise or sustain prices for products or services;  An inability to maintain appropriate relations with unions and employees;  The inability to achieve expected results from our acquisition activities;  Our ability to continue to pay cash dividends;  The amount and timing of repurchases of our common shares, if any; and  Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation S&P 500 All time high of $39.55 May 13th, 2014 Page 8 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 9 Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Page 10 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Page 13 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture)  Manufacturing alignment Page 14 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?